Alcon Expands Its Cell Therapy Ambitions With $550M Neurotech Pharma Acquisition

Alcon acquired Neurotech Pharmaceuticals for $550 million, adding the rare vision disorder cell therapy Encelto and its underlying platform technology to its portfolio. The deal follows Alcon's majority stake investment in Aurion Biotech last year, which is developing a corneal cell therapy. The acquisitions signal Alcon's strategic pivot toward cell therapy as a growth area within ophthalmology.